

## Angioimmunoblastic T-Cell Lymphoma

### Overview

Lymphoma is the most common blood cancer. The two main forms of lymphoma are Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL). Lymphoma occurs when cells of the immune system called lymphocytes, a type of white blood cell, grow and multiply uncontrollably. Cancerous lymphocytes can travel to many parts of the body, including the lymph nodes, spleen, bone marrow, blood, or other organs, and form a mass called a tumor. The body has two main types of lymphocytes that can develop into lymphomas: B lymphocytes (B cells) and T lymphocytes (T cells).

Angioimmunoblastic T-cell lymphoma (AITL) is a rare and often fast-growing form of peripheral T-cell lymphoma (PTCL). AITL and the follicular helper subtype of PTCL (PTCL-FH) share a common biology and are often grouped together in terms of treatment approaches. AITL accounts about 18 percent of PTCLs. AITL is more common in older people but can sometimes affect young adults as well. Symptoms of AITL include high fever, night sweats, skin rash, and autoimmune disorders such as autoimmune hemolytic anemia (AIHA) and immune thrombocytopenia (ITP). As a result of these autoimmune disorders, the body's immune system attacks its own cells and tissues, such as red blood cells (AIHA) or platelets (ITP).

Diagnosing AITL requires taking a *biopsy* (sample of the tumor tissue) and looking at the cells under a microscope. A series of other tests may be done to determine the extent, or stage, of the disease. These can include blood tests, a computed tomography (CT) scan, a positron emission tomography (PET) scan, a magnetic resonance imaging (MRI) scan, and a bone marrow biopsy.

The majority of patients with AITL are diagnosed with advanced-stage disease, either Stage III or Stage IV. In Stage III, affected lymph nodes are found both above and below the diaphragm. In Stage IV, one or more organs beyond the lymph nodes are affected, such as the bone, bone marrow, skin, or liver. Less extensive disease, Stage I or II, is rare in AITL. Patients with Stage I have localized disease that has not spread beyond the tumor; Stage II disease has spread only to a nearby lymph node.

### Treatment Options

Patients with AITL are most commonly treated with combinations of chemotherapy drugs. Recommended *frontline* (initial) therapy for the treatment of AITL is either a clinical trial or a multiagent chemotherapy

regimen, such as CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone). Sometimes higher doses of chemotherapy followed by stem cell transplantation may be added to multiagent chemotherapy. In cases where the goal is to treat the disease more mildly to primarily relieve symptoms, steroids may be used.

Disease *relapse* (returns after treatment) is common with this cancer. If the cancer returns or does not go away with initial therapy, there are several other treatment options available. Belinostat (Beleodaq) is approved for treatment of relapsed or *refractory* (does not respond to treatment) PTCL; patients with AITL were included in the clinical study that led to this approval. Belinostat is a histone deacetylase (HDAC) inhibitor that blocks tumor cells from growing and dividing, causing cell death. Similarly, another HDAC inhibitor, romidepsin (Istodax), has been approved to treat PTCL in patients who have received at least one prior therapy. Pralatrexate (Folotyn) was the first agent to be approved by the U.S. Food and Drug Administration (FDA) for the treatment of relapsed or refractory PTCL; patients with AITL were included in the clinical study that supported this indication. Treatments following relapse may include high-dose chemotherapy followed by an *autologous stem cell transplant* (patients receive their own stem cells) or an *allogeneic stem cell transplant* (patients receive stem cells from a donor). For additional information about stem cell transplantation, view the *Understanding Stem Cell Transplantation* publication on the Lymphoma Research Foundation's (LRF's) website at [lymphoma.org/publications](http://lymphoma.org/publications).

### Other Treatment Possibilities

Several drugs have been tested in small clinical trials (alone or in combination with current chemotherapy regimens) and show promise for the treatment of AITL, including brentuximab vedotin (Adcetris) and lenalidomide (Revlimid). Some other drugs used in other types of lymphoma that may occasionally be considered for the treatment of patients with AITL include alemtuzumab (Campath), bortezomib (Velcade), gemcitabine (Gemzar), and bendamustine (Treanda).

## Treatments Under Investigation

New treatments for AITL are being researched all the time. There are several drugs currently in clinical trials that are showing promising results, including:

- CPI-613
- MEDI-570
- Nivolumab (Opdivo)
- Plitidepsin

Combinations of other new drugs such as CHOP (doxorubicin, vincristine, cyclophosphamide, prednisone) and lenalidomide (Revlimid), or romidepsin (Istodax) plus CHOEP (doxorubicin, vincristine, cyclophosphamide, etoposide, prednisone) as frontline therapy. It is critical to remember that today's scientific research is continuously evolving. Treatment options may change as new treatments are discovered and current treatments are improved. Therefore, it is important that patients check with their physician or with LRF for any treatment updates that may have recently emerged.

## Clinical Trials

Clinical trials are crucial in identifying effective drugs and determining optimal doses for patients with lymphoma. Because AITL is a rare disease, clinical trial enrollment is critical for establishing more effective, less toxic treatments. The rarity of the disease also means that the most novel treatments are often available only through clinical trials. Patients interested in participating in a clinical trial should view the *Understanding Clinical Trials* fact sheet on LRF's website at [lymphoma.org/publications](http://lymphoma.org/publications), talk to their physician, or contact the LRF Helpline for an individualized clinical trial search by calling (800) 500-9976 or emailing [helpline@lymphoma.org](mailto:helpline@lymphoma.org).

## Follow-up

Disease relapse and infections are common with this cancer. It is important to seek medical attention for fever or other symptoms related to improper functioning of the immune system.

Patients with lymphoma should have regular visits with a physician who is familiar with their medical history and the treatments they have received. Medical tests (such as blood tests and CT scans or at

times PET scans) may be required at various times during remission to evaluate the need for additional treatment.

Some treatments can cause long-term side effects or late side effects, which can vary based on duration and frequency of treatments, age, gender, and the overall health of each patient at the time of treatment. A physician will check for these side effects during follow-up care. Visits may become less frequent the longer the disease remains in remission.

Patients and their caregivers are encouraged to keep copies of all medical records and test results as well as information on the types, amounts, and duration of all treatments received. This documentation will be important for keeping track of any side effects resulting from treatment or potential disease recurrences. LRF's award-winning *Focus On Lymphoma* mobile app ([lymphoma.org/mobileapp](http://lymphoma.org/mobileapp)) or the *Lymphoma Care Plan* ([lymphoma.org/publications](http://lymphoma.org/publications)) can help patients manage this documentation.

## Patient and Caregiver Support Services

A lymphoma diagnosis often triggers a range of feelings and concerns. In addition, cancer treatment can cause physical discomfort. One-to-one peer support programs, such as LRF's *Lymphoma Support Network*, connect patients and caregivers with volunteers who have experience with AITL, similar treatments, or challenges, for mutual emotional support and encouragement. Patients and loved ones may find this information useful whether the patient is newly diagnosed, in treatment, or in remission.

## Resources

LRF offers a wide range of resources that address treatment options, the latest research advances, and ways to cope with all aspects of lymphoma, including our award-winning mobile app. LRF also provides many educational activities, from in-person meetings to teleconferences and webcasts for people with lymphoma and AITL, as well as patient guides and e-Updates that provide the latest disease-specific news and treatment options. To learn more about any of these resources, visit our websites at [lymphoma.org/AITL](http://lymphoma.org/AITL) or [lymphoma.org](http://lymphoma.org), or contact the LRF Helpline at (800) 500-9976 or [helpline@lymphoma.org](mailto:helpline@lymphoma.org).

Contact the  
Lymphoma Research Foundation

Helpline: (800) 500-9976

[helpline@lymphoma.org](mailto:helpline@lymphoma.org)

Website: [lymphoma.org](http://lymphoma.org)

Medical reviewer:

Steven M. Horwitz, MD  
Memorial Sloan Kettering  
Cancer Center

Supported  
through  
grants from:



Genentech  
A Member of the Roche Group

Biogen

© 2018 Lymphoma Research Foundation

*Getting the Facts* is published by the Lymphoma Research Foundation (LRF) for the purpose of informing and educating readers. Facts and statistics were obtained using published information, including data from the Surveillance, Epidemiology, and End Results (SEER) Program. Because each person's body and response to treatment is different, no individual should self-diagnose or embark upon any course of medical treatment without first consulting with his or her physician. The medical reviewer, the medical reviewer's institution, and LRF are not responsible for the medical care or treatment of any individual.

Stay Connected  
through our social  
media

